Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 6/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27417581 | 0.93 | GLS (0.43) | GLSCCR5MEN1KMT2AKDM4E | |
| SCHEMBL27417428 | 0.93 | GLS (0.43) | GLSCCR5MEN1KMT2AKDM4E | |
| SCHEMBL31754206 | 0.93 | GLS (0.43) | GLSCCR5MEN1KMT2AKDM4E | |
| SCHEMBL27420904 | 0.92 | ALK (0.45) | GLSCCR5KDM4EALKGPBAR1 | |
| SCHEMBL27417456 | 0.92 | ALK (0.45) | GLSCCR5KDM4EALKGPBAR1 | |
| SCHEMBL27417431 | 0.89 | GLS (0.41) | GLSCCR5KMT2AKDM4EALK | |
| SCHEMBL27421807 | 0.89 | GLS (0.41) | GLSCCR5KMT2AKDM4EALK | |
| SCHEMBL27420532 | 0.88 | ALDH1A1 (0.40) | GLSCCR5KDM4EALKCHRM4 | |
| SCHEMBL27417956 | 0.87 | POLB (0.47) | GLSCCR5KMT2AKDM4EDPP4 | |
| SCHEMBL31754172 | 0.87 | GLS (0.44) | GLSCCR5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001859-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | JNANA THERAPEUTICS INC. | 2026-01-01 | — | — | US | disclosed |
| US-20240208923-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | JNANA THERAPEUTICS INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208923-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | JNANA THERAPEUTICS INC. | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208923-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | SLC18A2, SLC6A19, SLC1A1 | GLS 55/4885CCR5 4173/4885MEN1 3842/4885 |
| US-20260001859-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | SLC6A19, SLC6A15, SLC6A2 | GLS 224/4885CCR5 2005/4885MEN1 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.